The state of New Jersey currently has 419 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Recruiting
The purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Recruiting
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Summit Medical Group PA, Florham Park, New Jersey
Conditions: Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
Pancreatic Cancer Detection Consortium
Recruiting
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage I, Pancreatic Cancer Stage, Pancreatic Cancer Resectable, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Cancer Non-resectable
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Recruiting
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Cooper Hospital UNIV MED CTR., Camden, New Jersey
Conditions: Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v6, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Recruiting
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/24/2024
Locations: Research Site, East Brunswick, New Jersey
Conditions: Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
A Study of Blood Pressure Control During Cancer Treatment
Recruiting
The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure levels and the risk of cardiotoxicity in patients with cancer. Other studies have shown lowering blood pressure improves the health of patients. However, these studies have not included people with cancer. The PROTECT trial is testing a treatment strategy regarding intensive... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Breast Cancer, Cardiotoxicity
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Recruiting
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
Recruiting
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: MSK Basking Ridge, Basking Ridge, New Jersey +3 locations
Conditions: Advanced Breast Cancer
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors. The study will also identify a recommended dose for expansion (RDFE) in subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety e... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Titan Health Partners Llc Dba Astera Cancer Care, East Brunswick, New Jersey
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer
Peer Support For Young Adult Women With High Breast Cancer Risk
Recruiting
This trial will recruit young adult female relatives (YARs) of male or female carriers of BRCA1/2. YARs who consent to participate will be randomized to either a 3-session peer coach-led telephone counseling intervention or usual care navigation to peer support interventions provided by community organizations that support the hereditary cancer community. Study aims are to 1) Assess intervention effects on distress and decision making outcomes, including uptake of counseling for untested YARs, 2... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Breast Cancer Risk
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
Recruiting
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/22/2024
Locations: Virtua Health Inc, Marlton, New Jersey
Conditions: Colorectal Cancer
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Recruiting
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Atlantic Health, Morristown, New Jersey +1 locations
Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer